Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neurapas balance is a herbal medicinal product developed and manufactured by Pascoe Pharmazeutische Praeparate GmbH. It is a fixed-dose combination of three standardized plant extracts: *Hypericum perforatum* (St. John's Wort), *Passiflora incarnata* (Passionflower), and *Valeriana officinalis* (Valerian). The product is indicated for the treatment of mild to moderate depressive episodes accompanied by anxiety, nervous restlessness, and sleep disturbances. Its therapeutic effect is derived from the synergistic action of its components: St. John's Wort acts as a multi-reuptake inhibitor of serotonin, norepinephrine, and dopamine; Passionflower provides anxiolytic properties through GABAergic modulation; and Valerian serves as a mild sedative. Clinical trials have utilized quantitative EEG to demonstrate its pharmacological effects on brain activity, confirming its impact on central nervous system function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neurapas balance.